title: Lactobacillus plantarum 299v does not reduce enteric bacteria or bacterial translocation in patients undergoing colon resection.
abstract: BACKGROUND
  Probiotics may exert beneficial effects in the gastrointestinal tract. This randomized trial investigated the effect of the probiotic Lactobacillus plantarum 299v on the intestinal load of potentially pathogenic bacteria, bacterial translocation, and cell proliferation in elective colon surgery.
  
  
  METHODS
  Seventy-five patients were randomized to pre- and postoperative oral intake of Lactobacillus plantarum 299v or placebo. Rectal swabs and mucosal biopsies were taken before the start of intake, after 1 week, at surgery, and after 6 days, weeks, and months. Viable counts were quantified for clostridia, Enterobacteriaceae, Gram-negative anaerobes, and lactobacilli. Bacterial translocation was determined by the analysis of bacterial DNA genes in mesenteric lymph nodes. Ki-67 was used as a marker of cell proliferation in normal mucosa and tumor.
  
  
  RESULTS
  Lactobacillus plantarum 299v was given without adverse effects. Lactobacillus plantarum 299v as well as Enterobacteriaceae and Gram-negative anaerobes increased in the colon 1 week after the administration of Lactobacillus plantarum 299v. There were no significant differences between patients receiving Lactobacillus plantarum 299v and placebo in the incidence of bacterial translocation (27 vs. 13%) and postoperative complications (16 vs. 31%).
  
  
  CONCLUSIONS
  Lactobacillus plantarum 299v was established in the intestine, but no inhibitory effect on enteric bacteria, bacterial translocation, or postoperative complications was found. The mechanism behind the protective effects of probiotics found in animal and some human studies remain elusive and require further explorations. No adverse effects were recorded after the administration of high doses of Lactobacillus plantarum 299v.
authors.affiliation: Department of Clinical Sciences, Lund University, Malmö, Sweden. peter.mangell@med.lu.se
authors.forename: Peter
authors.initials: P
authors.lastname: Mangell
authors.forename: Henrik
authors.initials: H
authors.lastname: Thorlacius
authors.forename: Ingvar
authors.initials: I
authors.lastname: Syk
authors.forename: Siv
authors.initials: S
authors.lastname: Ahrné
authors.forename: Göran
authors.initials: G
authors.lastname: Molin
authors.forename: Crister
authors.initials: C
authors.lastname: Olsson
authors.forename: Bengt
authors.initials: B
authors.lastname: Jeppsson
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D018988:Bacterial Translocation / Q000187:drug effects* / Q000502:physiology; D001706:Biopsy; D049109:Cell Proliferation / Q000187:drug effects; D003106:Colon / Q000382:microbiology* / Q000473:pathology / Q000601:surgery*; D004311:Double-Blind Method; D017558:Elective Surgical Procedures; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000302:isolation & purification / Q000502:physiology; D005260:Female; D006089:Gram-Negative Anaerobic Bacteria / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D015994:Incidence; D048191:Lactiplantibacillus plantarum / Q000302:isolation & purification / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control; D019936:Probiotics / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use